
ተመደር የተመሰው የምተመው የተመሰው የተያሉ፣ የመቀር የመቀር

CARREST, AND EARLY AT ANALYSIS, THEORYS LAW ARE LARGE TO A ...



What is claimed is:


- A method for treating or inhibiting thrombosis in a subject comprising administering a composition comprising an effective amount of a P-selectin antagonist.
- The method of claim 1, wherein the P-selectin antagonist is a soluble 2. PSGL-1 protein or a fragment thereof having P-selectin ligand activity.
- The method of claim 2, wherein the soluble PSGL-1 protein is human 3. PSGL-1.
- 4. The method of claim 2, wherein the soluble PSGL-1 protein is a recombinant protein.
- 5. The method of claim 2, wherein the soluble PSGL-1 protein comprises an Fc portion of an immunoglobulin.
 - 6. The method of claim 5, wherein the immunoglobulin is human IgG₁.
- 7. The method of claim 2, wherein the soluble PSGL-1 protein is a recombinant human PSGL-Ig fusion protein.
- The method of claim 2, wherein the soluble PSGL-1 protein comprises an extracellular domain of human PSGL-1 protein, or a fragment thereof, having Pselectin ligand activity.
- 9. The method of claim 8, wherein the fragment comprises the amino acid sequence set forth in SEQ ID NO:2 from amino acid 42 to amino acid 60.
- 10. The method of claim 8, wherein the fragment comprises the amino acid sequence set forth in SEQ ID NO:2 from amino acid 42 to amino acid 88.
- 11. The method of claim 8, wherein the fragment comprises the amino acid sequence set forth in SEQ ID NO:2 from amino acid 42 to amino acid 118.
- 12. The method of claim 8, wherein the fragment comprises the amino acid sequence set forth in SEQ ID NO:2 from amino acid 42 to amino acid 189.

*** AUST 10, 140

- 13. The method of claim 8, wherein the fragment comprises the amino acid sequence set forth in SEQ ID NO:2 from amino acid 42 to amino acid 310.
- 14. The method of claim 2, wherein the soluble PSGL-1 protein comprises the amino acid sequence from amino acid 42 to amino acid 88 of SEQ ID NO:2 fused at its C-terminus to an Fc portion of an immunoglobulin.
- 15. The method of claim 8, wherein the soluble PSGL-1 protein further comprises an Fc portion of an immunoglobulin.
 - 16. The method of claim 1, wherein the subject is human.
- 17. The method of claim 1, wherein the P-selectin antagonist is administered to the subject prior to thrombus formation.
- 18. The method of claim 2, wherein the effective amount of soluble PSGL-1 protein or fragment thereof is between approximately 0.1 mg/kg and 10 mg/kg.
- 19. The method of claim 18, wherein the effective amount of soluble PSGL-1 protein is approximately 1 mg/kg.
- 20. The method of claim 19, wherein the effective amount of soluble PSGL-1 protein is selected from the group consisting of 0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 0.75 mg/kg, 1.0 mg/kg, 1.25 mg/kg, 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg, 3.0 mg/kg, and 3.5 mg/kg.
- 21. A method for inhibiting cell adhesion to blood vessels in a subject comprising administering a composition comprising an effective amount of soluble PSGL-1, or a fragment thereof having P-selectin ligand activity.
- 22. The method of claim 21, wherein the cells are selected from the group consisting of leukocytes and platelets.
- 23. A method for increasing the movement of cells relative to blood vessels in a subject comprising administering a composition comprising an effective amount of soluble PSGL-1, or a fragment thereof having P-selectin ligand activity.



consisting of leukocytes and platelets.



- 25. A method for inhibiting the effect of a thrombus-inducing agent in a subject comprising administering a composition comprising an effective amount of an effective amount of soluble PSGL-1, or a fragment thereof having P-selectin ligand activity.
- 26. The method of claim 25, wherein the effect of the thrombus inducing agent is on cells selected from the group consisting of leukocytes and platelets.
- 27. The method of claim 25, wherein the thrombus-inducing agent is LTC₄.